A KRAS-variant in Ovarian Cancer Acts As a Genetic Marker of Cancer Risk

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Jul 22

PMID 20647319

Citations 73

Authors

Elena Ratner

Lingeng Lu

Marta Boeke

Rachel Barnett

Sunitha Nallur

Lena J Chin

Cory Pelletier

Rachel Blitzblau

Renata Tassi

Trupti Paranjape

Pei Hui

Andrew K Godwin

Herbert Yu

Harvey Risch

Thomas Rutherford

Peter Schwartz

Alessandro Santin

Ellen Matloff

Daniel Zelterman

Frank J Slack

Joanne B Weidhaas

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is the single most deadly form of women's cancer, typically presenting as an advanced disease at diagnosis in part due to a lack of known risk factors or genetic markers of risk. The KRAS oncogene and altered levels of the microRNA (miRNA) let-7 are associated with an increased risk of developing solid tumors. In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene. Specimens obtained were tested for the presence of the KRAS-variant from nonselected OC patients in three independent cohorts, two independent ovarian case-control studies, and OC patients with hereditary breast and ovarian cancer syndrome (HBOC) as well as their family members. Our results indicate that the KRAS-variant is associated with more than 25% of nonselected OC cases. Further, we found that it is a marker for a significant increased risk of developing OC, as confirmed by two independent case-control analyses. Lastly, we determined that the KRAS-variant was present in 61% of HBOC patients without BRCA1 or BRCA2 mutations, previously considered uninformative, as well as in their family members with cancer. Our findings strongly support the hypothesis that the KRAS-variant is a genetic marker for increased risk of developing OC, and they suggest that the KRAS-variant may be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities.

Citing Articles

The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers.

Wang F, Zhou C, Zhu Y, Keshavarzi M Cell Biol Toxicol. 2024; 40(1):42.

PMID: 38836981 PMC: 11153289. DOI: 10.1007/s10565-024-09884-3.

The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer.

Chen B, Zhao L, Yang R, Xu T Front Genet. 2023; 14:1275154.

PMID: 38028615 PMC: 10665572. DOI: 10.3389/fgene.2023.1275154.

CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer.

Zhang X, Zheng X, Ying X, Xie W, Yin Y, Wang X J Transl Med. 2023; 21(1):334.

PMID: 37210575 PMC: 10199564. DOI: 10.1186/s12967-023-04136-0.

Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target.

Wang Y, Zhong B, Xu C, Zhan D, Zhao S, Wu H iScience. 2023; 26(2):106080.

PMID: 36824285 PMC: 9942120. DOI: 10.1016/j.isci.2023.106080.

Identification of seven hypoxia-related genes signature and risk score models for predicting prognosis for ovarian cancer.

Huang Y, Zhou Y, Zhang M Funct Integr Genomics. 2023; 23(1):39.

PMID: 36642729 PMC: 9841006. DOI: 10.1007/s10142-022-00956-3.

References

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View

Hirschhorn J . Genomewide association studies--illuminating biologic pathways. N Engl J Med. 2009; 360(17):1699-701. DOI: 10.1056/NEJMp0808934. View

Stratton J, Gayther S, Russell P, Dearden J, Gore M, Blake P . Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997; 336(16):1125-30. DOI: 10.1056/NEJM199704173361602. View

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H . Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11):3753-6. DOI: 10.1158/0008-5472.CAN-04-0637. View

Dahiya N, Sherman-Baust C, Wang T, Davidson B, Shih I, Zhang Y . MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008; 3(6):e2436. PMC: 2410296. DOI: 10.1371/journal.pone.0002436. View

Antoniou A, Easton D . Risk prediction models for familial breast cancer. Future Oncol. 2006; 2(2):257-74. DOI: 10.2217/14796694.2.2.257. View

Song H, Ramus S, Tyrer J, Bolton K, Gentry-Maharaj A, Wozniak E . A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009; 41(9):996-1000. PMC: 2844110. DOI: 10.1038/ng.424. View

10.

Sasaki R, Narisawa-Saito M, Yugawa T, Fujita M, Tashiro H, Katabuchi H . Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis. 2009; 30(3):423-31. DOI: 10.1093/carcin/bgp007. View

11.

Nelson H, Christensen B, Plaza S, Wiencke J, Marsit C, Kelsey K . KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer. 2009; 69(1):51-3. PMC: 2879467. DOI: 10.1016/j.lungcan.2009.09.008. View

12.

Lu L, Katsaros D, de la Longrais I, Sochirca O, Yu H . Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007; 67(21):10117-22. DOI: 10.1158/0008-5472.CAN-07-2544. View

13.

Risch H, Bale A, Beck P, Zheng W . PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1738-41. DOI: 10.1158/1055-9965.EPI-06-0272. View

14.

Ibanez-Ventoso C, Yang M, Guo S, Robins H, Padgett R, Driscoll M . Modulated microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell. 2006; 5(3):235-46. DOI: 10.1111/j.1474-9726.2006.00210.x. View

15.

Pharoah P, Antoniou A, Bobrow M, Zimmern R, Easton D, Ponder B . Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002; 31(1):33-6. DOI: 10.1038/ng853. View

16.

Christensen B, Moyer B, Avissar M, Ouellet L, Plaza S, McClean M . A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis. 2009; 30(6):1003-7. PMC: 2691138. DOI: 10.1093/carcin/bgp099. View

17.

Mishra P, Mishra P, Banerjee D, Bertino J . MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle. 2008; 7(7):853-8. DOI: 10.4161/cc.7.7.5666. View

18.

Goldstein D . Common genetic variation and human traits. N Engl J Med. 2009; 360(17):1696-8. DOI: 10.1056/NEJMp0806284. View

19.

Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J . Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat. 2008; 30(1):79-84. DOI: 10.1002/humu.20837. View

20.

Quaye L, Song H, Ramus S, Gentry-Maharaj A, Hogdall E, DiCioccio R . Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer. 2009; 100(6):993-1001. PMC: 2661781. DOI: 10.1038/sj.bjc.6604947. View